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Myelodysplastic syndrome (MDS) comprises a group of hematological disorders in which 
hematopoietic stem/precursor cells in the bone marrow do not develop properly into healthy blood 
cells. Allogeneic hematopoietic cell transplantation (HCT) represents a possible cure, but 10 to 50 % 
of patients relapse, which is suggestive of a poor outcome. Most relapses occur within 12 to 18 
months after HCT. However, there is no defined time point beyond which the patient is considered 
"safe" - some relapses are diagnosed several years after transplantation. 
The question thus arises: what factors determine who will relapse and when? This occupied the 
Clinical Research Division's Drs. Cecilia Yeung and Joachim Deeg, whose results from analysis of 
relapse patterns among 1,007 transplanted MDS patients were recently presented inBiology of 
Blood and Marrow Transplantation. "This is the first large study to examine risk factors for and 
features of late relapse after HCT for MDS," Dr. Yeung said, further explaining that this kind of in-
depth look at late-relapse clonal characteristics could help identify patients who might benefit from 
targeted interventions after HCT to prevent disease progression. 
Disease progression and relapse after HCT are mainly determined by changes in the structure or 
function of cells and chromosomes, referred to as clonal cytogenetic abnormalities, likely supported 
by somatic (i.e. non-inherited) mutations. Although there is limited knowledge about the prognostic 
effect of molecular abnormalities, recent findings indicate that MDS clones present at the time of 
post-HCT relapse often differ from those identified pre-HCT, although the "relapse clones" have yet 
to be properly characterized. 
In the patient cohort analyzed by Dr. Yeung and colleagues, relapses before 18 months were 
categorized as "early" and those after 18 months as "late", and differences in risk factors between 
the two data sets were assessed through logistic regression analysis. From the initial cohort, 973 
MDS patients were included; of those, 25 % eventually relapsed; 213 before 18 months (median 100 
days), and 41 after 18 months (median 2.6 years). As expected, the hazard of relapse in the entire 
cohort declined steadily, though without any distinct time point at which the trend changed 
significantly. The difference in median survival after relapse was not statistically significant between 
early- and late-relapsing patients (91 and 220 days, respectively; p = 0.07). Multivariable regression 
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analysis of patients who were relapse-free and alive at 18 months (n = 408) identified a number of 
risk factors, including the finding that MDS that had developed into acute myeloid leukemia implied 
higher risk of late relapse than untransformed MDS. Another conclusion was that late relapse was 
less likely among patients with chronic graft-versus-host disease (GVHD) compared to those without 
chronic GVHD - a finding that concurred with the documented graft-versus-leukemia/tumor effect. 
"The alloreactivity of donor cells is a major contributor to the eradication of the patient's disease," 
explained Dr. Yeung. 
In general, few significant differences were noted in characteristics of early- and late-relapsing 
patients. Poor-risk cytogenetics were associated with higher probability of early relapse, as was pre-
HCT conditioning with reduced-intensity regimens. Genetic analysis performed on sequential bone 
marrow samples from 36 late-relapsing patients revealed additional clonal abnormalities at relapse 
besides those detected in pre-HCT samples in 41 %; 30 % had their pre-HCT abnormalities replaced 
by new clones; 17 % exhibited the same clone pre-HCT and at relapse; and in 10 % no 
abnormalities were revealed for either time point. 
Three patients in the "late" group were further analyzed by chromosomal genomic array testing of 
pre-HCT and post-relapse DNA, to examine potentially prognostic alterations that may be 
undetectable by standard methods. Interestingly, post-relapse-unique abnormalities were discovered 
for all three patients. Still, higher-sensitivity techniques may be needed to confidently exclude the 
possibility of the deviations being present at very low levels already before HCT. 
Dr. Yeung concluded that further refined mutational analyses should be undertaken. "We 
hypothesized that late relapses may be due to an 'escape' from surveillance (by donor alloreactivity) 
due to the evolution of new clones/subclones. However, results do not show clear differences in 
clonal architecture between early and late relapse." The team, in collaboration with Dr. Jerry 
Radich's laboratory, will now continue the studies of MDS progression dynamics and molecular 
profiles through single cell techniques and massive deep sequencing, in addition to exploring 
emerging questions regarding late relapse versus "new disease", which might have to be handled 
differently. 
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Image provided by Dr. Cecilia Yeung 
(a) Bone marrow karyotypes before HCT (broken pie chart) and at 
the time of relapse (intact pie charts) in 213 patients with early 
relapse. (b) Bone marrow karyotypes before HCT (broken pie chart) 
and at the time of relapse (intact pie charts) in 41 patients with late 
relapse. 
 
